Tumor-associated Mucin 1 glyco-epitope (TA-MUC1)

Tumor-associated Mucin 1 (TA-MUC1) glyco-epitope refers to the specific, cancer-altered form of the Mucin 1 protein, a large transmembrane glycoprotein normally expressed on the apical surface of epithelial cells (UniProt: P15941). In healthy tissues, MUC1 is heavily O-glycosylated with long, branched carbohydrate chains that mask the protein backbone and provide lubrication and protection to the epithelium. However, in malignant cells, MUC1 loses its apical polarization and undergoes aberrant, truncated O-glycosylation, exposing the peptide core and creating unique glycopeptide epitopes such as Tn (GalNAc-Ser/Thr) and sialyl-Tn (STn) (Nath and Mukherjee, 2014). These TA-MUC1 epitopes are highly specific to tumor tissues and are virtually absent in healthy tissues, making them ideal targets for precision immunotherapy. Therapeutic strategies targeting TA-MUC1 include monoclonal antibodies like gatipotuzumab, which specifically recognizes the carbohydrate-induced conformational epitope, as well as antibody-drug conjugates and chimeric antigen receptor (CAR) T-cell therapies (Gooch et al., 2023). By targeting these cancer-specific glyco-forms, drugs aim to induce immune-mediated destruction of tumor cells while minimizing damage to normal epithelial tissues that express the heavily glycosylated, protected version of the protein (Glycotope GmbH, 2024).

Other names

MUC1-CMUC1-NCD227Epithelial membrane antigen (EMA)Polymorphic epithelial mucin (PEM)Tn-MUC1Sialyl-Tn-MUC1 (STn-MUC1)Thomsen-Friedenreich MUC1 (TF-MUC1)Cancer-associated MUC1KL-6

Binding to tumor-specific glycopeptide epitopes to induce antibody-dependent cellular cytotoxicity (ADCC), deliver cytotoxic payloads via antibody-drug conjugates, or direct T-cell mediated lysis through CAR-T cell recognition.